2 completed, 2 recruiting, 1 enrolling by invitation, 1 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Recruiting 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Precision BioSciences, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) PBGENE-DMD (IV) - Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | Phase 1 / Phase 2 | Recruiting | Precision BioSciences, Inc. | 18 | 2026-04-24 | 2026-10-21 |
| A Long-term Observational Study in Participants Who Have Received PBGENE-HBV PBGENE-HBV - Chronic HBV Infection | Enrolling by invitation | Precision BioSciences, Inc. | 45 | 2025-12-25 | 2026-04-22 | |
| Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B PBGENE-HBV - HEPATITIS B CHRONIC | Phase 1 | Recruiting | Precision BioSciences, Inc. | 45 | 2024-11-14 | 2026-08-24 |
| Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies PBCAR19B - CD19 Expressing Malignancies, Hematologic Malignancy | Phase 1 | Completed | Precision BioSciences, Inc. | 13 | 2021-06-16 | 2024-07-26 |
| A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma PBCAR269A, Fludarabine, Cyclophosphamide - Relapsed/Refractory Multiple Myeloma | Phase 1 | Terminated | Precision BioSciences, Inc. | 48 | 2020-04-30 | 2023-09-21 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL PBCAR20A, Fludarabine, Cyclophosphamide - Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse | Phase 1 / Phase 2 | Completed | Precision BioSciences, Inc. | 18 | 2020-03-24 | 2023-01-31 |
Hepatitis B, Chronic (2) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Muscular Dystrophies (1) · Muscular Dystrophy, Duchenne (1) · Recurrence (1)
Cyclophosphamide (2) · fludarabine (2) · nirogacestat (1)
United States (6) · Hong Kong (2) · Moldova (2) · New Zealand (2) · France (1) · Romania (1)
Monika Vainorius, MD (2) · Alan List, MD (1)